The Vanity Metric That Costs Lives
Every June, the internet turns blue. Ribbons are pinned, corporate logos get temporary makeovers, and press releases flood our feeds to announce ALS Awareness Month. We congratulate ourselves on "shining a light" on Amyotrophic Lateral Sclerosis.
It is a comforting ritual. It is also completely useless. Meanwhile, you can find similar events here: The Epidemiology of Extreme Heat Why Standard Reporting Misses the Target.
Let’s be brutally honest: awareness is a vanity metric. If awareness could cure a neurodegenerative disease, ALS would have been eradicated in 2014 when half the planet dumped buckets of ice water over their heads. That viral phenomenon raised over $115 million for the ALS Association. It was a massive marketing triumph. But over a decade later, the clinical reality for a diagnosed patient remains fundamentally grim: a death sentence with a two-to-five-year survival clock.
The lazy consensus driving these annual campaigns assumes that the primary barrier to curing ALS is that people simply do not care enough, or that funding for general research is too low. This diagnosis of the problem is entirely wrong. The bottleneck is not a lack of noise. The bottleneck is an archaic drug development pipeline, broken animal models that waste decades of research, and a regulatory framework that treats a rapidly fatal illness with the same bureaucratic foot-dragging as a cosmetic drug. To see the complete picture, check out the excellent article by Healthline.
Stop buying the ribbons. Stop sharing the hashtags. If we actually want to save lives, we have to dismantle the entire infrastructure of performative charity and focus on the cold, hard mechanics of translational science.
The Ice Bucket Illusion
I have spent years watching foundations pour millions into generic "basic research" grants that lead straight to academic dead ends. The public believes that every dollar donated goes toward a scientist holding a syringe containing the cure. The reality is a bureaucratic maze where funds are chewed up by institutional overhead, redundant studies, and papers that sit behind paywalls.
The Ice Bucket Challenge proved that money can be raised overnight. What it also proved is that throwing money at a systemic failure does not fix the system.
Consider how ALS research historically operates. A lab discovers a compound that slows down motor neuron degradation in a SOD1 mouse model. Everyone celebrates. A paper is published. A non-profit issues a celebratory newsletter. Then, the compound enters human clinical trials and fails completely.
Why? Because human ALS is incredibly heterogeneous. Only about 10% of cases are familial (genetic), and only a fraction of those involve the SOD1 mutation. The other 90% are sporadic. We have spent decades curing a specific type of genetic mutation in mice while ignoring the complex, multi-system failure that occurs in actual human beings.
The obsession with general awareness funding keeps feeding this loop. It prioritizes feel-good stories over structural reform. It funds the 50th study on the same mouse model because it is safe, predictable, and keeps the grant money flowing.
The True Bottlenecks: What June Stays Silent About
If we look at the actual barriers to progress, they have nothing to do with public recognition.
| The Awareness Myth | The Clinical Reality |
|---|---|
| We need more people to know what ALS stands for. | Everyone in neurology knows what it is; we lack validated biomarkers to track progression accurately. |
| More money for basic research will solve the crisis. | Capital is wasted on siloed data; researchers refuse to share raw clinical trial data with competitors. |
| The FDA needs to protect patients from unproven drugs. | Over-regulation is killing patients who are willing to take calculated risks on experimental therapies. |
Dismantling the "People Also Ask" Delusions
The public discourse around ALS is warped by a few fundamental misunderstandings that search engines perpetuate daily. Let’s correct them directly.
Does ALS funding go to the right places?
Mostly, no. A disproportionate amount of capital goes toward maintaining the infrastructure of the charities themselves or funding early-stage academic exploration that has no clear path to human translation. We do not need more exploratory science that concludes "more research is needed." We need targeted funding for open-science data repositories and adaptive clinical trials.
Why is there still no cure for ALS?
Because the traditional clinical trial system is built for chronic conditions, not rapid killers. By the time a patient is diagnosed, they have already lost a massive percentage of their motor neurons. Standard clinical trials take years to set up, require placebos for dying patients, and measure progression using subjective questionnaires like the ALSFRS-R (ALS Functional Rating Scale). Expecting a patient with a three-year lifespan to participate in a traditional three-year trial is a mathematical absurdity.
How can we accelerate treatments?
By abandoning the one-drug, one-trial model. The HEALEY ALS Platform Trial, led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, is a rare example of actual innovation. Instead of testing one drug at a time, a platform trial tests multiple treatments simultaneously against a single, shared placebo group. This cuts the number of patients on placebos, slashes costs, and accelerates timelines. This is where money should go—not to billboard campaigns.
The Open Data War
If you want to see where the real battle lies, look at data hoarding.
For decades, major pharmaceutical companies and academic institutions ran clinical trials, gathered data on patients, and then locked that data away in proprietary vaults. If a trial failed, the data was buried. This meant another company might waste five years and fifty million dollars testing a similar hypothesis, completely blind to the previous failure.
Imagine a scenario where every single piece of patient data—genomic sequencing, transcriptomics, clinical tracking, and post-mortem tissue analysis—was instantly uploaded to an open-access global registry. Every failure would immediately inform the next trial. Every success would be instantly verifiable.
Instead, our current awareness-driven funding model rewards individual institutions for building their own private empires. They compete for your June donation dollars by hyping up their exclusive breakthroughs, rather than collaborating on a unified front.
True progress requires enforcing absolute data transparency as a condition for receiving any public or charitable funding. If an institution refuses to share its raw de-identified patient data with the global scientific community, they should not receive a single cent.
The Regulatory Death Trap
We cannot talk about ALS without addressing the regulatory cowardice that stalls drug deployment.
The Food and Drug Administration (FDA) is designed to avoid risk. For a cholesterol drug or a mild antidepressant, this makes sense. The long-term safety profile must be ironclad because the target population is not facing imminent death.
But ALS patients do not have time for decade-long safety evaluations. For someone losing the ability to breathe, a drug with a 30% chance of severe side effects but a 20% chance of extending life by a year is a trade-off they are entirely willing to make. Yet, the regulatory pathway often demands rigid, large-scale Phase III trials that take years to design and execute.
We saw a brief break from this rigidity with the approval of Relyvrio (AMX0035) in 2022, driven by immense patient advocacy pressure. The drug showed a modest survival benefit in a Phase II trial. The FDA approved it, but when a larger Phase III trial failed to show efficacy in 2024, the manufacturer withdrew it from the market.
Critics pointed to this as a failure of early approval. They are wrong. It was a victory of the system working as it should for a terminal illness. Patients got access to a potentially life-saving drug early. When the data proved it didn't work at scale, it was pulled. That is exactly how high-stakes medicine should operate. The real failure is that we don't have fifty other drugs moving through that exact same rapid pipeline right now.
Shift Your Capital, Stop the Noise
If you want to actually move the needle on this disease, change how you direct your resources.
Do not donate to organizations that focus on general awareness or spend significant portions of their budget on marketing and walks. Look for entities that are actively restructuring the scientific workflow.
Support organizations that fund biomarker discovery. Without reliable blood or spinal fluid biomarkers (like neurofilament light chain), we cannot tell if a drug is working until months or years have passed. We need objective, molecular metrics to run fast, cheap trials.
Support institutions that are pioneering expanded access (compassionate use) programs, allowing dying patients to access experimental therapies outside of formal clinical trials. This provides immediate options to patients while generating real-world data that can inform future drug development.
The downside to this approach is that it is not flashy. It does not make for a viral video. Explaining the nuances of adaptive platform trials or biomarker validation to a general audience is difficult. It doesn't fit neatly on a t-shirt or a bracelet. But it is the only path that yields actual results.
The era of passive awareness must end. The next time June rolls around and you are asked to support ALS Awareness Month, decline. Demand accountability instead. Demand open data, regulatory flexibility, and an end to the duplication of failed science. Stop keeping the disease visible, and start making it curable.
